In-depth profiling of tumor tissue derived from malignant pleural mesothelioma patients identifies potential biomarkers predicting response to immune-checkpoint inhibitor therapy  

作　　者：Dmitri Shek Bo Gao Hema Mahajan Adnan Nagrial Matteo S.Carlino Fabio Luciani Scott A.Read Golo Ahlenstiel 

机构地区：[1]Blacktown Clinical School,Western Sydney University,Sydney,NSW 2148,Australia [2]Westmead Institute for Medical Research,Sydney,Nsw 2145,Australia [3]Blacktown Mt Druitt Hospital,Sydney,NSW 2148,Australia [4]Westmead Hospital,Sydney,Nsw 2145,Australia [5]Westmead Clinical School,University of Sydney,Sydney,NSW 2145,Australia [6]Institute of Clinical Pathology and Medical Research,Sydney,NSW 2145,Australia [7]Melanoma Institute Australia,Sydney,NSW 2065,Australia [8]School of Medical Sciences,University of New South Wales,Sydney,NSW 2052,Australia [9]Garvan Institute for Medical Research,Sydney,NSW 2010,Australia

出　　处：《Genes & Diseases》2024年第6期28-31,共4页基因与疾病（英文）

基　　金：The NCT04631731 is funded by (i)Western Sydney Local Health District Research and Education Grant 2021, (ii)Bristol Myers Squibb (CA209-6KR),and (iii)BGI ANZ Genetic Service Grant 2021.

摘　　要：Malignant pleural mesothelioma(MPM)is a rare and aggressive cancer with low survival probability as it is generally diagnosed at later stages.'Using a combination of immune-checkpoint inhibitors(ICls)ipilimumab(IPl)and nivolumab(NivO)as a first-line treatment for unresectable MPM,the CheckMate 743 trial reported higher overall survival and prolonged duration of response compared with traditional chemotherapy.

关 键 词：PLEURAL CHEMOTHERAPY IMMUNE 

分 类 号：R73[医药卫生—肿瘤]